<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Liguzinediol (LZDO) <z:chebi fb="21" ids="35701">ester</z:chebi> <z:chebi fb="0" ids="50266">prodrugs</z:chebi> 3-5 were synthesized and evaluated in vitro and in vivo for their potential use in prolonging the half-life of the parent drug LZDO (1a) in vivo </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="50266">Prodrugs</z:chebi> 3-5 were found to display a potent positive inotropic effect on the myocardium, without the risk of <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="50266">Prodrugs</z:chebi> 3-5 rapidly underwent enzymatic hydrolysis to release the parent compound LZDO in 1-3 h in rat liver microsomes and rat plasma </plain></SENT>
<SENT sid="3" pm="."><plain>The half-life of the parent compound was prolonged after intragastric administration of <z:chebi fb="0" ids="50266">prodrug</z:chebi> 3, which was found to be a superior <z:chebi fb="0" ids="50266">prodrug</z:chebi> candidate for increasing myocardial contractility </plain></SENT>
</text></document>